Planned
BI 1403-0032 - Brigimadlin safety roll-over trial
A Phase II, single arm, open-label, long-term safety rollover trial of oral brigimadlin in patients with solid tumours
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Boehringer Ingelheim
- More information : NCT06619509
- Indication :
- Internal reference number : s69421
Brightline-4 - BI1403-0019
A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 treatment in patients with advanced treatment-naïve or pre-treated dedifferentiated liposarcoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Boehringer Ingelheim
- More information : NCT06058793
- Indication :
- Internal reference number : s68468
Ongoing
SaLuDo - PM1183-C-010-22
Randomized, Controlled, Open-label, Phase IIb /III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : PharmaMar / ICON plc
- More information : NCT06088290
- Indication : Metastatic Leiomyosarcoma
- Internal reference number : s68148
Closed
I5B-MC-JGDQ
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Eli Lilly
- More information : NCT03126591
- Indication :
- Internal reference number : s60237
ANITA EORTC 1506
A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : EORTC
- More information : NCT02808247
- Indication :
- Internal reference number : s60174
ANNOUNCE I5B-MC-JGDJ
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Eli Lilly
- More information : NCT02451943
- Indication :
- Internal reference number : s58322
DeFi NIR301DT
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors (DTs)/ Aggressive Fibromatosis (AF)
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Springworks Therapeutics
- More information : NCT03785964
- Indication :
- Internal reference number : s62673
EPIZYME EZH-202
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Epizyme
- More information : NCT02601950
- Indication :
- Internal reference number : s62571
MANTRA - RAIN-3201
A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients
with Dedifferentiated Liposarcoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Rain Therapeutic
- More information : NCT04979442
- Indication :
- Internal reference number : s65705
TRUST EZH-501
Tazemetostat Rollover Study : An Open-Label Rollover Study
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : Epizyme
- More information : NCT02875548
- Indication :
- Internal reference number : s62571